(Circulation. 1999;100:II-114.)
© 1999 American Heart Association, Inc.
Surgery for Coronary Artery Disease |
Isolated Left Anterior Descending Coronary Artery Disease
Percutaneous Transluminal Coronary Angioplasty Versus Stenting Versus Left Internal Mammary Artery Bypass Grafting
From the Mid America Heart Institute, Kansas City, Mo.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Single-vessel coronary artery disease is usually treated with PTCA; however, this approach when applied to the left anterior descending coronary artery (LAD) is hampered by high restenosis rates, often approaching 50%. Coronary stenting (STENT) and left internal mammary artery bypass grafting of the LAD (LIMA-LAD) are other options that have been successfully used for single-vessel LAD disease. The optimal mode of revascularization for patients with isolated single-vessel LAD disease is unclear. The purpose of the present study was to examine PTCA versus STENT versus LIMA-LAD with respect to short- and intermediate-term outcomes.
Methods and Results—This was an observational retrospective cohort study comparing in-hospital and intermediate-term outcomes and functional class among patients with isolated single-vessel LAD disease revascularization. Consecutive eligible patients were grouped according to their initial revascularization procedure and systematically followed up. A total of 704 patients qualified for the study: 469 in the PTCA group, 137 in the STENT group, and 98 in the LIMA-LAD group. Follow-up data were complete for 97% of patients and averaged 27±13 months. In-hospital mortality for the PTCA, STENT, and LIMA-LAD groups was 1.1%, 0%, and 0% (P=0.51), respectively. Median hospital stays after the procedure for the respective treatment groups were 1, 1, and 5 days (P<0.001), and occurrences of in-hospital myocardial infarction were 0.9%, 1.5%, and 1.0% (P=NS). Repeat revascularization procedures were performed in 30%, 24%, and 5% of the PTCA, STENT, and LIMA-LAD groups (P=<0.001 for LIMA-LAD versus other groups, P=0.11 for PTCA versus STENT). Actuarial 2-year mortality was 3.9%, 2.6%, and 1% in the PTCA, STENT, and LIMA-LAD groups (P=0.33).
Conclusions—Revascularization for isolated LAD disease using PTCA, STENT, or LIMA-LAD results in low in-hospital adverse event rates and good long-term results. Repeat procedures are required less often after LIMA-LAD than after either PTCA or STENT. Long-term mortality was not statistically different, but the trend was for the lowest mortality with LIMA-LAD, a somewhat higher mortality with STENT, and the highest mortality with PTCA.
Key Words: angioplasty • stents • grafting • coronary disease • bypass • revascularization
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The left anterior descending coronary artery (LAD) is almost always the largest of the 3 epicardial coronary arteries. The LAD typically subtends
50% of the left
ventricular myocardial mass, or approximately twice as much
as either the right or the left circumflex coronary
arteries.1 2 Patients with significant LAD disease,
particularly when the proximal vessel is involved, have been noted to
have an adverse cardiac prognosis compared with patients with
coronary artery disease that does not involve the
LAD.3 4 5 Although PTCA, coronary stenting (STENT),
and left internal mammary artery bypass grafting (LIMA-LAD) are all
used frequently for this high-risk lesion, the optimal approach remains
unclear. No prior study has compared the outcomes of patients with
isolated LAD disease treated with PTCA versus STENT versus LIMA-LAD
surgery. The purpose of the present study was to compare short- and intermediate-term outcomes of patients with isolated LAD disease who received PTCA versus STENT versus LIMA-LAD surgery.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Overview
This was an observational retrospective cohort study comparing in-hospital and intermediate-term morbidity and mortality rates as well as functional status among patients with isolated single-vessel LAD revascularization who received PTCA or STENT or LIMA-LAD.
Identification of Eligible Patients
Patients were retrospectively identified for inclusion in the
study from the PTCA and coronary artery bypass surgery
databases at the Mid America Heart Institute, Kansas City, Mo. Patients
were eligible for inclusion if they underwent their procedure between
the dates of July 1, 1993, and October 31, 1997. Patients with
angiographically documented, isolated single-vessel LAD
revascularization with a 
70% luminal diameter
stenosis (usually estimated by 1 of a core group of 5
experienced invasive cardiologists) in the proximal or midvessel
location were candidates for the study. The decision as to which, if
any, revascularization procedure to use for each
specific patient was made by the clinical physicians managing the case,
often in consultation between cardiologists and surgical colleagues and
the patient. Systematic guidelines about when to use the different
modalities for revascularization of the LAD were
not used. Only patients who received LIMA-LAD were included in the
surgical group. Any patient with prior coronary stenting or any
type of prior cardiac surgery was excluded as well as any patient
presenting with an evolving acute myocardial infarction. All
patients who underwent any concomitant surgery, such as valve
replacement or repair, or carotid surgery were excluded from the
surgical group.
If the patient underwent a subsequent procedure after the initial index revascularization procedure, the results were analyzed by the "intention to treat" principle. For example, patients who initially underwent PTCA of the LAD but required stenting of the vessel at a separate procedure remote from the initial coronary angioplasty procedure were analyzed as PTCA patients.
By use of these parameters, a total of 704 consecutive patients with isolated proximal or mid-LAD disease who underwent a revascularization procedure were identified. This group included 469 PTCA patients, 137 STENT patients, and 98 LIMA-LAD patients.
Baseline Data
The patient groups were very similar with respect to baseline
demographic and anatomic variables. Details are outlined in Table 1
. The mean ages were similar (62±13,
60±12, and 61±11 years) as were the mean ejection fractions (49±10,
52±10, and 52±10) in the PTCA, STENT and LIMA-LAD groups,
respectively. The incidence of unstable angina at baseline was
significantly higher in the LIMA-LAD group. Patients in the PTCA group
underwent coronary angioplasty alone or in conjunction with
directional atherectomy in 5.6% of cases and rotational atherectomy in
16%. In patients who received stent implantation, 5.8% of patients
had rotational atherectomy and 1.5% had directional atherectomy.
Values were P=0.003 (rotational atherectomy) and
P=0.05 (directional atherectomy) when the STENT and PTCA
patients were compared. All patients in the STENT group underwent PTCA
with stenting. Patients who received an intracoronary stent
were discharged on ticlopidine and aspirin. High-pressure balloon
inflation was used, and stent underexpansion was avoided; in some
cases, intravascular ultrasound was used as a guide. Angiography
revealed coronary obstructions in non-LAD vessels in a small
number of the PTCA, STENT, and CABG groups (70% stenosis in
the right coronary artery: 1.2%, 1.4%, and 5.6%,
respectively; in the circumflex artery: 2.5%, 1.4%, and 14.0%,
respectively). Note that CABG patients had a higher incidence of
totally obstructed non-LAD vessels in the right coronary and
left circumflex arteries (PTCA patients: 0.3% and 0.7%, respectively;
STENT patients: 5.6% and 0.8%, respectively; and CABG patients: 0.7%
and 2.8%, respectively). Previous PTCA had been performed in 33.5%,
34.3%, and 41.8% (P=0.29) of PTCA, STENT, and CABG
patients, respectively. Previous LAD PTCA had been performed in 22%,
25.5%, and 28.6% of the PTCA, STENT, and CABG patients, respectively
(P=0.34). Proximal LAD disease was present more often in
the LIMA-LAD group than the other 2 groups (Table 1). Other
major baseline characteristics of the 3 groups were similar; these
characteristics included the sex of the patient, baseline
creatinine, and diabetes.
|
Follow-Up
Follow-up was complete in 97% of patients and was performed
between November 1997 and February 1998. A comprehensive follow-up
survey used both mail and telephone questionnaires. In addition to the
follow-up survey, subsequent hospital and outpatient records were
reviewed on all patients who reported any major events.
Statistical Analysis
Kaplan-Meier survival analyses were performed to
evaluate differences in intermediate outcome among the 3 groups.
Event-free survival was defined as freedom from death, myocardial
infarction, and repeat revascularization
procedures. Procedural myocardial infarction was defined as the
presence of new Q waves that were 0.03 seconds in width and/or one
third of the QRS complex in 2 contiguous leads. A multivariable
analysis was carried out evaluating independent predictors of
subsequent revascularization procedures. Repeat
revascularization was modeled by using the Cox
proportional hazards regression model. The treatment group (PTCA versus
STENT versus LIMA-LAD) was forced into the model, and stepwise
variable selection was used to identify further significant
factors. Categorical variables were compared using Student’s
t test and 
2 methods.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In-hospital events were rare among all 3 groups (Table 2
). In-hospital death occurred in 5
(1.1%) of the 469 PTCA patients; no patient died in hospital in the
STENT or LIMA-LAD group (P=NS). The median length of stay
after the procedure was only 1 day for both the PTCA and STENT groups;
this was significantly shorter than the median stay of 5 days in the
LIMA-LAD group (P<0.001). In-hospital transient
ischemic attack without permanent neurological sequelae
occurred in 2 patients in the LIMA-LAD group; no patient suffered a
postprocedural neurological complication in the PTCA or STENT group
(P=NS).
|
Intermediate-term follow-up was obtained in 97% of patients, with a
mean follow-up of 27±13 months. The frequency of repeat
revascularization procedures was significantly
higher in both the PTCA and STENT groups compared with the LIMA-LAD
group (Figure 1). The need for a
subsequent revascularization procedure in the STENT
group (24%) was marginally lower than in the PTCA group (30%,
P=0.11). Frequency of myocardial infarction was low in all
groups, without any meaningful differences between them. The 2-year
actuarial mortality trended lowest (1.1%) in the LIMA-LAD group
compared with 2.6% in the STENT group and 3.9% in the PTCA group,
although the differences did not meet statistical significance
(P=0.33) (Figure 2). The
survival advantage of LIMA-LAD over PTCA was exaggerated in patients
who had proximal LAD rather than mid-LAD disease. Patients with
proximal LAD disease that underwent PTCA had a 2-year mortality of
5%.
|
|
By use of multivariable analysis modeling, the only
resulting significant baseline factors predicting need for subsequent
procedures were PTCA (odds ratio, 4.7 versus LIMA-LAD), STENT (odds
ratio, 3.3 versus LIMA-LAD), and diabetes (odds ratio, 1.45 versus
nondiabetics) (Table 3).
|
Total event-free survival, calculated using actuarial (Kaplan-Meier)
methodology, was substantially better in the LIMA-LAD group than in the
PTCA or STENT group (Figure 3).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study showed that revascularization for isolated LAD disease using PTCA, STENT, or LIMA-LAD resulted in low in-hospital morbidity and mortality rates and good intermediate-term results. Repeat revascularization was required significantly more often after both PTCA and STENT than after LIMA-LAD, and event-free survival was superior in the LIMA-LAD group. Intermediate-term mortality was not significantly different, but consistent trends were noted, with the lowest mortality in the LIMA-LAD group, a slightly higher mortality rate in the STENT group, and the highest mortality after PTCA.
In general, patients with single-vessel coronary artery disease are treated with medical therapy or PTCA. In a study comparing angioplasty with medicine,6 69 of the 212 patients with single-vessel disease who were randomly assigned to PTCA or medical therapy had a significant stenosis in the proximal LAD. At follow-up after 6 months, the PTCA patients had superior exercise tolerance and improved anginal status compared with the medically treated patients. However, PTCA of the LAD is limited by the frequent occurrence of restenosis.7 8 Compared with PTCA of the proximal LAD, STENT has been documented to result in a significantly decreased risk of restenosis.9 10 11 A trial involving 120 patients with symptomatic isolated LAD stenosis randomized patients to STENT or PTCA.9 The restenosis rates at 12 months were 19% for the stented group versus 40% for the PTCA group (P=0.02). Additionally, 12-month rates of event-free survival were 87% after stenting versus 70% after angioplasty (P=0.04).
CABG surgery using LIMA-LAD has been documented to be an effective treatment strategy for isolated stenosis of the proximal LAD.12 Studies have been performed comparing LIMA-LAD with PTCA of the LAD. One study showed similar long-term survival rates in these 2 groups, with a greater need for repeat revascularization procedures in the PTCA group and a lower incidence of overall cardiac events in the patients who underwent LIMA-LAD.13 Another study in which patients were randomly assigned to bypass surgery, PTCA, or medical therapy indicated that patients who underwent surgery that included LIMA-LAD had a significantly lower incidence of cardiac events during follow-up than did patients assigned to PTCA or medical therapy.14 In 2 large database studies, hazard-analysis risk adjustment revealed that patients with LAD disease, especially in the proximal segment, had superior intermediate-term outcomes after CABG surgery than after PTCA.3 4 In single-or double-vessel disease not involving the LAD, outcomes were similar after bypass surgery or PTCA. Follow-up studies extending for 17 years indicate that people with single-vessel LAD disease have long-term survival rates after LIMA-LAD that are as good or better than the rates in an age-matched population without coronary disease at baseline.15
The present study shows, as do prior studies,16 that STENT is superior to PTCA with respect to need for repeat revascularization procedures. However, in the present study, 24% of patients still required another procedure after STENT. On the other hand, repeat procedures after LIMA-LAD were quite uncommon and occurred significantly less often than after either PTCA or stenting.
CABG surgery does entail substantially higher early morbidity rates than do percutaneous approaches. The median postprocedure length of stay was 5 days after LIMA-LAD versus only 1 day for either PTCA or STENT. The in-hospital mortality rates, however, were similar in the 3 groups. Although a decreased length of stay has been shown to carry initial cost and patient comfort advantages, the need for repeat revascularization procedures during follow-up at least partially offsets these early benefits of the less invasive approach.17
Study Limitations
The present study is not a randomized trial; thus, baseline
differences between the groups may have accounted for some of the
observed differences. However, the findings were very
consistent with other recent reports concerning these
procedures. Technique and technology continue to improve rapidly in the
field of coronary revascularization. For
instance, coronary stents continue to evolve with improved
designs and potential for adjunctive therapy, such as
intracoronary radiation, that may reduce rates of
restenosis.18 Minimally invasive CABG surgery
without using cardiopulmonary bypass is being explored as a
less traumatic option for LIMA-LAD.19 These changes when
incorporated into clinical practice may alter the relative outcomes in
patients with isolated LAD disease.
The present study confirms that the patient with isolated LAD disease has 3 effective revascularization options. Additional studies will be important in evaluating the effectiveness of aggressive medical therapy (eg, lipid-lowering drugs, antiplatelet therapy, and ß-blockers) as either an alternative to or adjunctive therapy for coronary revascularization in patients with isolated LAD disease.20
|
Footnotes |
|---|
Reprint requests to James H. O’Keefe, Jr, MD, Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Mahmarian JJ, Pratt CM, Boyce TM, Verani MS. The variable extent of jeopardized myocardium in patients with single-vessel coronary artery disease: quantification by thallium-201 single photon emission computed tomography. J Am Coll Cardiol. 1991;17:355–362.[Abstract]
2. O’Keefe JH, Grines CL, DeWood MA, Bateman TM, Christian TF, Gibbons RJ. Factors influencing myocardial salvage with primary angioplasty. J Nucl Cardiol. 1995;2:35–41.[Medline] [Order article via Infotrieve]
3.
Hannan EL, Racz MJ, McCallister BD, Ryan TJ, Arani DT,
Isom OW, Jones RH. A comparison of three-year survival following
coronary artery bypass graft surgery and
percutaneous transluminal coronary angioplasty.
J Am Coll Cardiol. 1999;33:63–72.
4.
Jones RH, Kesler K, Phillips HR III, Mar DB, Smith PK,
Nelson CL, Newman MF, Reves JG, Anderson RW, Califf RM. Long-term
survival benefits of coronary artery bypass grafting and
percutaneous transluminal angioplasty in patients with
coronary artery disease. J Thorac Cardiovasc
Surg. 1996;111:1013–1025.
5. Klein LW, Weintraub WS, Agarwal JB, Schneider RM, Seelans PA, Katz RI, Helfant RH. Prognostic significance of severe narrowing of the proximal portion of the left anterior descending coronary artery. Am J Cardiol. 1986;58:42–46.[Medline] [Order article via Infotrieve]
6. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med. 1992;326:10–16.[Abstract]
7. Burtt DM, Parisi AF. Proximal left anterior descending vessel disease: the role of PTCA. In: Ellis SG, Holmes DR Jr, eds. Strategic Approaches in Coronary Intervention. Baltimore, Md: Williams & Wilkins, 1996.
8. Frierson JH, Dimas AP, Whitlow PL, Hollman JL, Marsalese DL, Simpfendorfer CC, Dorosti K, Franco I. Angioplasty of the proximal left anterior descending coronary artery: initial success and long-term follow-up. J Am Coll Cardiol. 1992;19:745–751.[Abstract]
9.
Versaci F, Gaspardone A, Tomai F, Crea F, Ghiariello
L, Gioffree PA. A comparison of coronary-artery stenting with
angioplasty for isolated stenosis of the proximal left anterior
descending coronary artery. N Engl J Med. 1997;336:817–822.
10.
Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch
W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P. A
comparison of balloon-expandable-stent implantation with balloon
angioplasty in patients with coronary artery disease.
N Engl J Med. 1994;331:489–495.
11.
Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP,
Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M. A randomized
comparison of coronary-stent placement and balloon angioplasty
in the treatment of coronary artery disease. N Engl
J Med. 1994;331:496–501.
12.
Cameron A, Davis KB, Green G, Schaff HV.
Coronary bypass surgery with internal-thoracic-artery grafts:
effects on survival over a 15-year period. N Engl J
Med. 1996;334:216–219.
13. Goy JJ, Eeckhout E, Burnand B, Vogt P, Stauffer JC, Ilurni M, Stumpe F, Ruchat P, Sadeghi H, Kappenberger L. Coronary angioplasty versus left internal mammary artery grafting for isolated proximal left anterior descending artery stenosis. Lancet. 1994;343:1449–1453.[Medline] [Order article via Infotrieve]
14. Hueb WA, Bellotti G, de Oliveira SA, Arie S, de Albuquerque CP, Jatene AD, Pileggi F. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol. 1995;26:1600–1605.[Abstract]
15. Killen DA, Wathanacharoen S, Reed WA, Piehler JM, Borkon AM, Gorton ME, Muehlebach GF. Coronary artery bypass for isolated disease of the left anterior descending artery. Tex Heart Inst J. 1998;25:181–184.[Medline] [Order article via Infotrieve]
16. Macaya C, Serruys PW, Ruygrok P, Suryapranata H, Mast G, Klugmann S, Urban P, denn Heijer P, Koch K, Simon R, Morice MC, Crean P, Bonnier H, Wijus W, Danchin N, Bourdonnec C, Morel MA. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. J Am Coll Cardiol. 1996;27:255–261.[Abstract]
17. Cohen DJ, Breall JA, Ho KK, Weintraub RM, Kuntz RE, Weinstein MC, Baim DS. Economics of elective coronary revascularization: comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. J Am Coll Cardiol. 1993;22:1052–1059.[Abstract]
18.
King SB III, Williams DO, Chougule P, Klein JL, Waksman
R, Hilstead R, Macdonald J, Anderberg K, Crocker IR. Endovascular
B-radiation to reduce restenosis after coronary balloon
angioplasty. Circulation. 1998;97:2025–2030.
19.
Boden WE, O’Rourke RA, Crawford MH, Blaustein AS,
Deedwania PC, Zoble RG, Wexler LF, Kleiger RE, Pepine CJ, Ferry DR,
Chow BK, Lavori PW. Outcomes in patients with acute non-Q-wave
myocardial infarction randomly assigned to an invasive as compared with
a conservative management strategy. N Engl J Med. 1998;338:1785–1792.
20.
Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L,
Title LM, Eisenberg D, Shurzinske L, McCormick LS. Aggressive
lipid-lowering therapy compared with angioplasty in stable coronary
artery disease: Atorvastatin versus Revascularization Treatment
Investigators. N Engl J Med.. 1999;341:70–76.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||